Frequently asked questions
Frequently asked questions
Jump to a question:
Farname-Diagnosis is a startup led by a dedicated team of scientists, researchers, and clinical experts working to revolutionize healthcare diagnostics. We specialize in developing advanced point-of-care testing devices, with a current focus on early-stage ovarian cancer detection. Supported by accelerators at the University of Toronto, we are committed to making accurate, affordable, and accessible diagnostic solutions a reality.
Our device uses a novel biosensor technology that detects lysophosphatidic acid (LPA), an early biomarker for ovarian cancer. Unlike current diagnostics, which often identify ovarian cancer at later stages, our solution is designed for early detection, potentially improving patient outcomes significantly.
Early detection of ovarian cancer greatly increases the chances of successful treatment. Many existing diagnostic methods only detect ovarian cancer at advanced stages, leading to poor survival rates. Our goal is to make early-stage detection possible, allowing for more effective interventions.
Our point-of-care device is designed for use in gynecological clinics, medical laboratories, and healthcare facilities without specialized equipment. It’s simple enough to be used by healthcare providers in areas with limited access to specialized diagnostic resources.
Our device is currently in the prototype development phase. We are working on clinical validation, regulatory approval, and further testing to ensure accuracy and safety. Stay tuned for updates on availability!
To minimize environmental impact and costs, our device is designed with the potential for recycling the solid components. This feature allows for sustainable use over time.
We appreciate interest from both healthcare professionals and the community! You can follow our updates, spread awareness about the importance of early cancer detection, or contact us for potential partnership and support opportunities.